Buchumschlag

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Xuwen Lin, Mei Xie, Jie Yao, Xidong Ma, Lin Qin, Xu‐Mei Zhang, Jialin Song, Xinyu Bao, Xin Zhang, Yinguang Zhang, Yiming Liu, Wenya Han, Yiran Liang, Ying Jing, Xinying Xue
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Clinical and Translational Medicine
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
von: Ailing Cao, et al.
Veröffentlicht: (2026)

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer
von: Antoine Desilets, et al.
Veröffentlicht: (2024)

Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer
von: Ying Cheng, et al.
Veröffentlicht: (2024)

Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics
von: Yue Zhao, et al.
Veröffentlicht: (2026)

Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non‐small‐cell lung cancer
von: Ke Xu, et al.
Veröffentlicht: (2024)

The co‐location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non‐small cell lung cancer
von: Guangyu Fan, et al.
Veröffentlicht: (2024)

Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer
von: Xiaoshen Zhang, et al.
Veröffentlicht: (2024)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
von: Linda Wanika, et al.
Veröffentlicht: (2024)

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer
von: Ximo Zhang, et al.
Veröffentlicht: (2024)

Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers
von: Chenglin Yang, et al.
Veröffentlicht: (2024)

CXCR5 and TLR4 signals synergistically enhance non‐small cell lung cancer progression
von: Ji Hye Shin, et al.
Veröffentlicht: (2024)

Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
von: Xiao‐dan Wan, et al.
Veröffentlicht: (2025)

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights
von: Anqi Lin, et al.
Veröffentlicht: (2025)

B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential
von: Zizhuo Li, et al.
Veröffentlicht: (2024)

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
von: Luca Marzano, et al.
Veröffentlicht: (2024)

Spatial omics accelerate the study of cancer‐associated fibroblasts in non‐small lung cancer
von: Haozhen Liu, et al.
Veröffentlicht: (2024)

Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study
von: Boya Zhao, et al.
Veröffentlicht: (2024)

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
von: Yu Wang, et al.
Veröffentlicht: (2024)

Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study
von: Pulin Li, et al.
Veröffentlicht: (2024)

Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
von: Vahid Yaghoubi Naei, et al.
Veröffentlicht: (2024)

Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer
von: Haoran Li, et al.
Veröffentlicht: (2024)

Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer
von: Yuichiro Suzukawa, et al.
Veröffentlicht: (2026)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
von: Weijiao Xu, et al.
Veröffentlicht: (2025)

Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast–chondrocyte crosstalk
von: Enbo Zhang, et al.
Veröffentlicht: (2026)

Inflammatory‐associated myeloid dendritic cells reveals associations between chronic lung diseases and lung cancer
von: Zhiyu Chen, et al.
Veröffentlicht: (2024)

Unveiling miR‐451a and miR‐142‐3p as prognostic markers in non‐small cell lung cancer via small extracellular vesicle liquid biopsy
von: Miranda Burdiel, et al.
Veröffentlicht: (2026)

Molecular mechanisms of ageing in cancer development and therapeutic response: Translational implications for precision oncology
von: Laiba Husain
Veröffentlicht: (2025)

Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells
von: Haoxian Ke, et al.
Veröffentlicht: (2025)

Anti‐PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest
von: Mengjia Qian, et al.
Veröffentlicht: (2025)

Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
von: Li Li, et al.
Veröffentlicht: (2024)

Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non‐small cell lung cancer
von: Jie Tang, et al.
Veröffentlicht: (2024)

Engineering exosomes for Alzheimer's disease: Multi‐target therapeutic strategies from pathogenesis to clinical translation
von: Yuehan Zhang, et al.
Veröffentlicht: (2025)

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
von: Huanxiang Chen, et al.
Veröffentlicht: (2024)

Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer
von: Pei Lin, et al.
Veröffentlicht: (2025)

Persistent lineage plasticity driving lung cancer development and progression
von: Fanchen Meng, et al.
Veröffentlicht: (2025)

Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer
von: Liuer He, et al.
Veröffentlicht: (2024)

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance
von: Junyan Li, et al.
Veröffentlicht: (2026)

High‐risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database
von: Weili Kong, et al.
Veröffentlicht: (2024)

Investigating the biological effects of socioeconomic adversity in cancer
von: David Füller
Veröffentlicht: (2024)

Glutamate as a therapeutic strategy to promote liver regeneration
von: María del Mar Rigual, et al.
Veröffentlicht: (2025)